Share Email Print

Proceedings Paper

Preliminary study of verteporfin photodynamic therapy in a canine prostate model
Author(s): Zheng Huang; Fred Hetzel; Ken Dole; David Luck; Jill Beckers; Don Maul
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Photodynamic therapy (PDT) mediated with verteporfin was investigated as an alternative modality for the treatment of prostate cancer. Materials and Methods: Vertoporfin-mediated photodynamic effects on the prostate and its adjacent structures (underlying colon and bladder) were evaluated in a healthy canine model. Interstitial prostate PDT was performed by irradiating individual lobes with a diode laser (689 nm) and 1-cm cylindrical diffuser fibers at various light doses and drug-light intervals (DLI) to activate the IV administrated photosensitizer (0.5 or 2 mg/kg). The sensitivity of the adjacent tissues to Vertoporfin-PDT was determined by superficially irradiating the serosal surface of the bladder and colon with a microlens fiber. The prostate and adjacent tissues were harvested one-week after the treatment and subjected to histopathological examination. Results: Histopathological examinations confirmed that verteporfin PDT could destroy a clinically significant volume of prostatic tissue in the animal model. At the drug dose of 0.5 mg/kg, the light irradiation of 100 J/cm could induce a lesion diameter of 2 cm at DLI of 15 min and 1.2 cm at DLI of 3 hrs, respectively. This implies a strong influence of DLI on the lesion volume. The shorter DLI might produce stronger vascular effect and therefore more severe tissue damage. The colon was more sensitive to verteporfin PDT than the bladder. At the possible light dose level caused by light scattering during intra-prostate irradiation, the damage to the bladder and colon were superficial and minimal. Conclusions: The preliminary results clearly demonstrate that verteporfin PDT could be an effective means to destroy prostate gland and its usefulness for the treatment of prostate cancer is worth further investigation.

Paper Details

Date Published: 13 July 2009
PDF: 6 pages
Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73801Y (13 July 2009); doi: 10.1117/12.822930
Show Author Affiliations
Zheng Huang, HealthONE Alliance (United States)
Fred Hetzel, HealthONE Alliance (United States)
Ken Dole, HealthONE Alliance (United States)
David Luck, HealthONE Alliance (United States)
Jill Beckers, HealthONE Alliance (United States)
Don Maul, Pre-Clinical Research Services, Inc. (United States)

Published in SPIE Proceedings Vol. 7380:
Photodynamic Therapy: Back to the Future
David H. Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?